Cardiome Pharma says vernakalant (iv) beats amiodarone in European study

VANCOUVER, B.C. - Cardiome Pharma Corp. (TSX:COM) said Thursday that a Phase 3 study in Europe found vernakalant (iv) performed better than amiodarone in treating atrial fibrillation or an irregular heart rhythm....More